The Effects of Anti-Dementia and Nootropic Treatments on the Mortality of Patients with Dementia: A Population-Based Cohort Study in Taiwan

PLoS One. 2015 Jun 22;10(6):e0130993. doi: 10.1371/journal.pone.0130993. eCollection 2015.

Abstract

Background: Few studies have examined the contribution of treatment on the mortality of dementia based on a population-based study.

Objective: To investigate the effects of anti-dementia and nootropic treatments on the mortality of dementia using a population-based cohort study.

Methods: 12,193 incident dementia patients were found from 2000 to 2010. Their data were compared with 12,193 age- and sex-matched non-dementia controls that were randomly selected from the same database. Dementia was classified into vascular (VaD) and degenerative dementia. Mortality incidence and hazard ratios (HRs) were calculated.

Results: The median survival time was 3.39 years (95% confidence interval [CI]: 2.88-3.79) for VaD without medication, 6.62 years (95% CI: 6.24-7.21) for VaD with nootropics, 3.01 years (95% CI: 2.85-3.21) for degenerative dementia without medication, 8.11 years (95% CI: 6.30-8.55) for degenerative dementia with anti-dementia medication, 6.00 years (95% CI: 5.73-6.17) for degenerative dementia with nootropics, and 9.03 years (95% CI: 8.02-9.87) for degenerative dementia with both anti-dementia and nootropic medications. Compared to the non-dementia group, the HRs among individuals with degenerative dementia were 2.69 (95% CI: 2.55-2.83) without medication, 1.46 (95% CI: 1.39-1.54) with nootropics, 1.05 (95% CI: 0.82-1.34) with anti-dementia medication, and 0.92 (95% CI: 0.80-1.05) with both nootropic and anti-dementia medications. VaD with nootropics had a lower mortality (HR: 1.25, 95% CI: 1.15-1.37) than VaD without medication (HR: 2.46, 95% CI: 2.22-2.72).

Conclusion: Pharmacological treatments have beneficial effects for patients with dementia in prolonging their survival.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Cohort Studies
  • Dementia / drug therapy*
  • Dementia / mortality*
  • Dihydroergocristine
  • Dihydroergotamine
  • Donepezil
  • Galantamine
  • Humans
  • Indans
  • Memantine
  • Neuroprotective Agents / therapeutic use*
  • Nootropic Agents / therapeutic use*
  • Piperidines
  • Piracetam
  • Proportional Hazards Models
  • Retrospective Studies
  • Rivastigmine
  • Taiwan
  • Time Factors

Substances

  • Indans
  • Neuroprotective Agents
  • Nootropic Agents
  • Piperidines
  • Dihydroergocristine
  • Galantamine
  • Dihydroergotamine
  • Donepezil
  • Rivastigmine
  • Memantine
  • Piracetam

Grants and funding

This work was supported by grant number NSC 98-2314-B-075-029 from the National Science Council, Taiwan, and grant number VGH V103C–201 from Taipei Veterans General Hospital, Taipei, Taiwan.